肌层浸润性膀胱癌的保留膀胱综合治疗  

Multimodality bladder-sparing treatment options for muscle-invasive bladder cancer

作　　者：许传亮 曾蜀雄 Xu Chuanliang;Zeng Shuxiong(Department of Urology,Changhai Hospital of Naval Medical University,Shanghai 200433,China)

机构地区：[1]海军军医大学第一附属医院泌尿外科,上海200433

出　　处：《中华泌尿外科杂志》2022年第6期407-410,共4页Chinese Journal of Urology

基　　金：上海市2020年度科技创新行动计划(22140903700、20Y11904800)。

摘　　要：随着新药研发、医疗技术进步和肿瘤分子生物学研究的进展,保留器官手术成为肿瘤外科治疗的发展趋势。本文围绕如何严格筛选合适的肌层浸润性膀胱癌患者行保留膀胱综合治疗及相关治疗策略、疗效、发展趋势等进行阐述。With the development of new drugs,advances in medical technology and progressions in tumor molecular biology,organ preservation surgery has become the new trend for tumor treatment.Here,we discussed how to select right muscle-invasive bladder cancer patient with strict criteria for multimodality bladder-sparing treatment,and we reviewed the new treatment options,outcomes and trend of development for bladder-sparing treatments.

关 键 词：膀胱肿瘤 肌层浸润膀胱肿瘤 保留膀胱 治疗 

分 类 号：R737.14[医药卫生—肿瘤]